H
Hanna Rennert
Researcher at Cornell University
Publications - 107
Citations - 3630
Hanna Rennert is an academic researcher from Cornell University. The author has contributed to research in topics: Autosomal dominant polycystic kidney disease & Cancer. The author has an hindex of 34, co-authored 100 publications receiving 3090 citations. Previous affiliations of Hanna Rennert include University of Pennsylvania & NewYork–Presbyterian Hospital.
Papers
More filters
Journal ArticleDOI
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Himisha Beltran,Himisha Beltran,Kenneth Eng,Kenneth Eng,Juan Miguel Mosquera,Juan Miguel Mosquera,Alexandros Sigaras,Alessandro Romanel,Hanna Rennert,Myriam Kossai,Myriam Kossai,Chantal Pauli,Chantal Pauli,Bishoy Faltas,Jacqueline Fontugne,Jacqueline Fontugne,Kyung Park,Jason R. Banfelder,Jason R. Banfelder,Davide Prandi,Neel Madhukar,Neel Madhukar,Tuo Zhang,Tuo Zhang,Jessica Padilla,Noah Greco,Terra J. McNary,Erick Herrscher,David Wilkes,Theresa Y. MacDonald,Hui Xue,Vladimir Vacic,Anne-Katrin Emde,Dayna M. Oschwald,Adrian Y. Tan,Zhengming Chen,Colin Collins,Martin E. Gleave,Yuzhuo Wang,Dimple Chakravarty,Marc H. Schiffman,Robert Kim,Robert Kim,Fabien Campagne,Brian D. Robinson,Brian D. Robinson,David M. Nanus,Scott T. Tagawa,Jenny Xiang,Agata Smogorzewska,Francesca Demichelis,Francesca Demichelis,David S. Rickman,David S. Rickman,Andrea Sboner,Andrea Sboner,Olivier Elemento,Olivier Elemento,Mark A. Rubin,Mark A. Rubin +59 more
TL;DR: The majority of advanced, treatment-resistant tumors across tumor types harbor biologically informative alterations, and the establishment of a clinical trial for WES of metastatic tumors with prospective follow-up of patients can help identify candidate predictive biomarkers of response.
Journal ArticleDOI
Use of Bisphosphonates and Risk of Postmenopausal Breast Cancer
TL;DR: The use of bisphosphonates for longer than 1 year was associated with a 28% relative reduction in the risk of postmenopausal breast cancer.
Journal ArticleDOI
Clinical, pathologic, and molecular features of early-onset colorectal carcinoma
Rhonda K. Yantiss,Mahmoud Goodarzi,Xi Kathy Zhou,Hanna Rennert,Edyta C. Pirog,Barbara F. Banner,Yao-Tseng Chen +6 more
TL;DR: Results indicate that early-onset carcinomas commonly show pathologic features associated with aggressive behavior and posttranslational regulation of mRNA and subsequent protein expression may be particularly important to the development of colorectal carcinomas in young patients.
Journal ArticleDOI
Genetic risk assessment in carrier testing for spinal muscular atrophy.
TL;DR: It is reported that approximately 7% of unaffected individuals without a family history of SMA have three or four copies of SMN1, implying a higher frequency of chromosomes with two copies ofSMN1 than previously reported.
Journal ArticleDOI
A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews
Hanna Rennert,Dani Bercovich,Ayala Hubert,Dvora Abeliovich,Uri Rozovsky,Anat Bar-Shira,Sonya Soloviov,Letizia Schreiber,Haim Matzkin,Haim Matzkin,Gad Rennert,Luna Kadouri,Tamar Peretz,Yuval Yaron,Yuval Yaron,Avi Orr-Urtreger,Avi Orr-Urtreger +16 more
TL;DR: Data suggest that the 471delAAAG null mutation is associated with PRCA in Ashkenazi men, however, additional studies are required to determine whether this mutation confers increased risk for PR CA in this population.